CSI Market
Sign In | Register

Bristol myers Squibb (BMY) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BMY Annual Cash Flow →
This page allows investors to follow Bristol myers Squibb's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income2,678.00
Depreciation & amortization594.00
Amortization of Other Assets0.00
Impairment charges0.00
Impairment of Long-Lived Assets to be Disposed of412.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories14.00
Stockbased compensation0.00
Restructuring Charges0.00
Share-based Compensation146.00
Prepaid expenses0.00
Sale of businesses0.00
Deferred Income Tax Expense Benefit Including Discontinued Operations-
Proceeds From Collaboration-
Pensionsettlementsandamortization-
Divestituregainsandroyalties-
Divestiture Gains And Royalties-34.00
Assetacquisitioncharge-
Income taxes348.00
Equity Method Investment, Realized Gain (Loss) on Disposal-134.00
Increase (Decrease) in Receivables1,687.00
Increase (Decrease) in Accounts Payable409.00
Increase (Decrease) in Other Accrued Liabilities-3,495.00
Pension contribution0.00
Insurance recoverable0.00
Other Working Capital-1,636.00
Other Noncash Income (Expense)21.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities94.00
Discontinued operations0.00
Net Cash flow from Operating Activities1,104.00
Investing Activities
Capital Expenditures-347.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities359.00
Payments to Acquire Marketable Securities-781.00
Proceeds from other investments0.00
Divestitureandotherproceeds-
Proceeds From Sale Of Equity Securities Fv Ni391.00
Divestiture And Other Proceeds312.00
Purchases of other investments0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Purchases of Investments0.00
Purchases of non-current assets0.00
Payments to Acquire Businesses, Net of Cash Acquired-65.00
Proceeds from Sale of Equity Method Investments0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Sale of assets0.00
Notes receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-131.00
Financing Activities
Short-term debt Net321.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-500.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock0.00
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net0.00
Other net0.00
Proceeds Termination Interest Rate Swap-
Interestrateswapcontractterminations-
Proceeds From Issuance Of Shares Under Share Based Compensation Plans-
Payments For Proceeds From Stock Option Exercises And Other Adjustments-98.00
Dividends paid to minority interests0.00
Dividends paid-1,283.00
Net Cash Flow from Financing Activities-1,560.00
Effect of exchange rate on cash flow-48.00
Discontinued operations0.00
Free Cash Flow757.00
Total Cash Flow-635.00
4 historic quarters locked

Sign in to unlock the full Bristol myers Squibb cash flow history.

Sign In Create Free Account

About Bristol Myers Squibb Co Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: July 30, 2026
  • Source: bmy-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000014272-26-000020

Figures are derived from filed reports and may be restated. Historical data is subject to revision.